Abstract: SA-PO500
Efficacy and Safety of Renal Denervation in the Maintenance Hemodialysis Patients with Hypertension: A Single-Center Study
Session Information
- Hypertension and CVD: Clinical - II
November 04, 2023 | Location: Exhibit Hall, Pennsylvania Convention Center
Abstract Time: 10:00 AM - 12:00 PM
Category: Hypertension and CVD
- 1602 Hypertension and CVD: Clinical
Authors
- Luo, Yuan, The Second Affiliated Hospital of Nanjing Medical University, Nanjing, Jiangsu, China
- Xu, Zhuo, The Second Affiliated Hospital of Nanjing Medical University, Nanjing, Jiangsu, China
- Wei, Guiling, The Second Affiliated Hospital of Nanjing Medical University, Nanjing, Jiangsu, China
- Gu, Chunfeng, The Second Affiliated Hospital of Nanjing Medical University, Nanjing, Jiangsu, China
- Ye, Hong, The Second Affiliated Hospital of Nanjing Medical University, Nanjing, Jiangsu, China
- Yang, Junwei, The Second Affiliated Hospital of Nanjing Medical University, Nanjing, Jiangsu, China
Background
Hypertension, a characteristic symptom in patients undergoing maintenance hemodialysis (MHD), is strongly linked to elevated hospitalization and mortality rates. Percutaneous renal denervation is a novel adjunctive treatment for hypertension, and we observed its efficacy and safety in patients undergoing maintenance dialysis.
Methods
Hypertension patients who underwent hemodialysis for more than 3 months were recruited. The eligible patients were between 18 and 70 years old, with office systolic blood pressure ranging from >150 mmHg to <180 mmHg, while concurrently taking three or more stable doses of antihypertensive medications for at least 6 months. Before enrollment, patients underwent a 28-day standardized treatment with antihypertensive medications. Those whose office systolic blood pressure remained between ≥150 mmHg and ≤180 mmHg after the treatment were included. Patients were subjected to follow-up assessments at 1, 3, and 6 months. The primary endpoints were a change in office systolic blood pressure, and changes in antihypertensive medication types and dosages from baseline to 6 months for the renal artery denervation.
Results
Between April 2021 and April 2023, among 26 enrolled patients, 12 patients who fulfilled the qualifying criteria underwent RDN surgery. The average age of the 12 patients was 43.4±10.60 years, with an average duration of dialysis of 2.4±1.14 years. At 3 months, the office systolic blood pressure reduction was -21.1mmHg（SD 5.7）. At 6 months, the office systolic blood pressure reduction was -17.3mmHg（SD 3.8）. At 6 months, only one patient required a reduction in the dosage of one medication, while the remaining patients maintained consistent types and dosages of medications as prior to the procedure. There were a total of 3 cases of adverse events, with 2 cases of minor hematoma at the femoral artery puncture site and 1 case of rectal bleeding in a patient with hemorrhoids.
Conclusion
At 6 months of follow-up，RDN produced a clinically meaningful blood pressure reduction，independent of concomitant antihypertensive medications. The application of RDN in patients undergoing maintenance hemodialysis is efficacy and safety.
Funding
- Government Support – Non-U.S.